非小细胞肺癌200例临床观察与分析

Clinical observation and analysis of 200 patients with non-small cell lung cancer

目的探讨特罗凯治疗非小细胞肺癌的临床疗效和安全性。方法选取非小细胞肺癌患者200例,随机分为有可比性的三组,其中A组49例,给予对症支持治疗;B组64例,在A组基础上给予培美曲塞治疗;C组87例,给予特罗凯治疗。对三组治疗效果以及两种药物的不良反应进行比较。结果应用特罗凯及培美曲塞治疗非小细胞癌中位PFS明显长于仅给予支持治疗的患者,有统计学意义(P<0.05);而特罗凯与培美曲塞两种治疗方式之间比较差异不明显(P>0.05);C组患者不良反应发生率明显高于对照组,两组比较差异明显,有统计学意义(P<0.05)。结论特罗凯治疗非小细胞肺癌是安全、有效而方便的。

Objective To observe the clinical efficacy and safety of Tarceva in the treatment of patients with non-small cell lung cancer.Methods 200 patients with non-small cell lung cancer were selected and randomly divided into 3 groups.The group A（49 cases） was given symptomatic treatment,the group B（64 cases） was given pemetrexed treatment on the basis of the group A,and the group C（87 cases） were given Tarceva treatment.The curative effect of the 3 groups and adverse reactions of the two kinds of medicine were compared.Results The median PFS of patients treated with Tarceva and pemetrexed was obviously longer than that of patients with support treatment with statistical significance（P〈0.05）,but there was no significant difference between Tarceva treatment and pemetrexed treatment（P〈0.05）.The incidence of adverse reactions was evidently higher in the group C than in the control group（P〈0.05）.Conclusion Tarceva therapy is a safe,effective and convenient method in the treatment of patients with non-small cell lung cancer,which is worthy of widely clinical application.